If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
|Podcasts|March 4, 2022
Pharmacy Focus Episode 42: Current Mental Health Treatment Needs
There are a few options that can help with the current mental health epidemic, although more studies are recommended to perfect these treatments.
Advertisement
In this week’s episode, we will be discussing clinician search data focused on mental health treatment needs with Dr. Stacy Miller, senior content management consultant at Wolters Kluwer Health. If you would like to nominate a pharmacist or pharmacy staff member as a Pharmacy Hero, email AAntrim@pharmacytimes.com!
Advertisement
Related to this article
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Experts highlighted how Diamond-Blackfan anemia illustrates the scientific, financial, and manufacturing challenges that can prevent promising gene therapies for ultra-rare diseases from reaching patients.
Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
2
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
3
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
4
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
5